title: Perspectives of arterial gene therapy for the prevention of restenosis.
abstract: Restenosis remains the main limitation of interventional cardiology. Restenosis is an important target for gene therapy since it is frequent (30% of patients), costly (estimated $2 billion annually), refractory to all pharmacological therapies, and related, at least in part, to smooth muscle cell proliferation which is an inviting target for antiproliferative molecular strategies. Because cell division is ultimately controlled by intranuclear events, the protein product of genes selected for their antiproliferative effects usually remains inside the cells. Consequently, the transfer of growth-inhibitory genes needs to be efficient-i.e., involve a large proportion of smooth muscle cells populating the angioplasty site. To date, adenoviral vectors are, by far, the most efficient vectors to perform in vivo arterial gene delivery. These vectors, as well as others, have been recently used to demonstrate that therapeutic genes encoding cytolytic (thymidine kinase) or cytostatic (hypophosphorylatable retinoblastoma protein, endothelial nitric oxide synthase, gax, etc.) products successfully inhibit smooth muscle cell proliferation and related intimal hyperplasia. Despite substantial progress, major technical issues remain to be addressed before gene therapy is applied to clinical restenosis. First-generation recombinant adenoviruses evoke both cellular and humoral immune responses leading to local toxicity and transient gene expression. Moreover, the low efficiency of gene transfer to atherosclerotic arteries may further impair the biological effect of antiproliferative genes. Finally, restenosis is a multifactorial phenomenon in which intimal hyperplasia plays an important but not exclusive role. Prevention of constrictive remodeling should also be taken into account in an integrated genetic strategy to prevent restenosis.
authors.affiliation: Department of Cardiology A Hôpital Bichat, Paris, France.
authors.forename: L J
authors.initials: LJ
authors.lastname: Feldman
authors.forename: O
authors.initials: O
authors.lastname: Tahlil
authors.forename: G
authors.initials: G
authors.lastname: Steg
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D001158:Arteries; D003327:Coronary Disease / Q000517:prevention & control* / Q000628:therapy; D003331:Coronary Vessels; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D012008:Recurrence